
-
Cocrystal Pharma NasdaqCM:COCP Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Location: 19805 North Creek Parkway, Bothell, WA, 98011, United States | Website: https://www.cocrystalpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
10.63M
Cash
6.921M
Avg Qtr Burn
N/A
Short % of Float
0.09%
Insider Ownership
36.35%
Institutional Own.
7.36%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Oral CC-42344 Details Influenza | Phase 2a Data readout | |
CC-31244 (Pan-genotypic NS5B NNI) Details Hepatitis C | Phase 2a Update | |
CDI-988 Details COVID-19, Norovirus | Phase 1 Update | |
Inhaled CC-42344 Details Influenza | Phase 1 Initiation | |
CDI-45205 Details COVID-19 | IND Submission |